Aspira Women’s Health (NASDAQ:AWH) Receives New Coverage from Analysts at started coverage on shares of Aspira Women’s Health (NASDAQ:AWHFree Report) in a research note published on Sunday. The firm issued a hold rating on the stock.

Separately, Cantor Fitzgerald reaffirmed a neutral rating and issued a $3.30 target price on shares of Aspira Women’s Health in a research report on Wednesday, April 10th.

Get Our Latest Research Report on Aspira Women’s Health

Aspira Women’s Health Trading Down 2.8 %

Shares of Aspira Women’s Health stock opened at $2.08 on Friday. The company’s fifty day simple moving average is $2.92 and its 200-day simple moving average is $3.61. The company has a market cap of $25.90 million, a price-to-earnings ratio of -1.43 and a beta of 1.50. Aspira Women’s Health has a 1 year low of $2.00 and a 1 year high of $6.75.

Aspira Women’s Health (NASDAQ:AWHGet Free Report) last issued its earnings results on Tuesday, May 21st. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.03). The firm had revenue of $2.15 million during the quarter, compared to the consensus estimate of $2.10 million. Aspira Women’s Health had a negative return on equity of 1,099.32% and a negative net margin of 163.95%. During the same period last year, the business earned ($10.94) earnings per share. As a group, research analysts forecast that Aspira Women’s Health will post -1.3 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of AWH. Northeast Financial Consultants Inc bought a new position in shares of Aspira Women’s Health during the third quarter valued at $126,000. Quantum Private Wealth LLC lifted its holdings in shares of Aspira Women’s Health by 76.8% during the fourth quarter. Quantum Private Wealth LLC now owns 50,156 shares of the company’s stock valued at $205,000 after acquiring an additional 21,788 shares during the period. Finally, B. Riley Wealth Advisors Inc. lifted its holdings in shares of Aspira Women’s Health by 39.0% during the third quarter. B. Riley Wealth Advisors Inc. now owns 125,374 shares of the company’s stock valued at $672,000 after acquiring an additional 35,177 shares during the period. 12.19% of the stock is owned by institutional investors.

Aspira Women’s Health Company Profile

(Get Free Report)

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.

See Also

Receive News & Ratings for Aspira Women's Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aspira Women's Health and related companies with's FREE daily email newsletter.